Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Spinal Muscular Atrophy (SMA) Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SMN2 drug discovery (optimized for transgenic mouse models and humanized assays). Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SMN2 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View SMN2 Products |
| Gene Delivery | SMN2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View SMN2 Products |
| Benchmark Ab | Anti-SMN2 Antibody Recombinant positive control for Western Blot and IHC. |
View SMN2 Products |
| Validator | SMN2 siRNA Set For knockdown verification in cell-based assays. |
View SMN2 Products |
| Related Target A | SMN1 Primary disease-causing gene homolog for selectivity profiling. |
View SMN1 Products |
| Related Target B | DMD Dystrophin for neuromuscular cross-pathway analysis. |
View DMD Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| SMN1 vs SMN2 Selectivity | Human/Mouse ortholog and paralog proteins available with >95% purity for precise binding assays. |
| Splicing Modifier Screening | High-fidelity HEK293 Expressed proteins ensuring native-like folding for small molecule interaction. |
| Lack of Controls | Validated Benchmark Antibodies included for in vivo biomarker tracking. |
| False Positives in HT Screening | Validated siRNA included for specificity checks in reporter cell lines. |
Live SMN2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SMN2 therapeutics is intensifying, with major players shifting focus from traditional ASOs to small molecule splicing modifiers and next-generation gene therapies. As first-generation therapies (like nusinersen and risdiplam) establish standard-of-care, the next wave of R&D is targeting optimized systemic delivery, enhanced CNS penetrance, and combinatorial approaches to maximize functional SMN protein production.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | Roche, PTC Therapeutics | Spinal Muscular Atrophy | Selectivity Assay (Need High-Purity WT vs Paralog Proteins) |
| ASO (Antisense) | Biogen, Ionis | SMA (Pediatric/Adult) | Reporter Assays (Need Stable Lentivirus Cell Lines) |
| Gene Therapy | Novartis | SMA Type 1 | Expression Validation (Need sequence-verified Abs) |